Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Price & Overview
NASDAQ:CELZ • US22529Y4089
Current stock price
2.25 USD
+0.03 (+1.35%)
Last:
The current stock price of CELZ is 2.25 USD. Today CELZ is up by 1.35%. In the past month the price increased by 13.07%. In the past year, price increased by 12.5%.
CELZ Key Statistics
52-Week Range1.504 - 6.25
Current CELZ stock price positioned within its 52-week range.
1-Month Range1.95 - 2.48
Current CELZ stock price positioned within its 1-month range.
- Market Cap
- 8.325M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.71
- Dividend Yield
- N/A
CELZ Stock Performance
Today
+1.35%
1 Week
+0.45%
1 Month
+13.07%
3 Months
+11.39%
Longer-term
6 Months -29.02%
1 Year +12.50%
2 Years -49.32%
3 Years -65.30%
5 Years N/A
10 Years N/A
CELZ Stock Chart
CELZ Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CELZ. When comparing the yearly performance of all stocks, CELZ turns out to be only a medium performer in the overall market: it outperformed 62.53% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CELZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CELZ. While CELZ has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CELZ Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported3K
EPS Surprise %
Revenue Surprise %
CELZ Forecast & Estimates
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 806.67% is expected in the next year compared to the current price of 2.25.
For the next year, analysts expect an EPS growth of 43.91% and a revenue growth -62.5% for CELZ
Analysts
Analysts82.86
Price Target20.4 (806.67%)
EPS Next Y43.91%
Revenue Next Year-62.5%
CELZ Financial Highlights
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -3.71. The EPS decreased by -0.54% compared to the year before.
Income Statements
Revenue(TTM)6.00K
Net Income(TTM)-6.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.77% | ||
| ROE | -79.78% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%35.42%
Sales Q2Q%0%
EPS 1Y (TTM)-0.54%
Revenue 1Y (TTM)-45.45%
CELZ Ownership
Ownership
Inst Owners3.49%
Shares3.70M
Float3.66M
Ins Owners0.34%
Short Float %4.28%
Short Ratio3.51
CELZ Industry Overview
CELZ operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
CELZ Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CELZ
Company Profile
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Company Info
IPO: 2009-05-01
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What does CREATIVE MEDICAL TECHNOLOGY do?
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Can you provide the latest stock price for CREATIVE MEDICAL TECHNOLOGY?
The current stock price of CELZ is 2.25 USD. The price increased by 1.35% in the last trading session.
What is the dividend status of CREATIVE MEDICAL TECHNOLOGY?
CELZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of CELZ stock?
CELZ has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 806.67% is expected in the next year compared to the current price of 2.25.
What is the GICS sector and industry of CELZ stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) operates in the Health Care sector and the Biotechnology industry.
What is the outstanding short interest for CREATIVE MEDICAL TECHNOLOGY?
The outstanding short interest for CREATIVE MEDICAL TECHNOLOGY (CELZ) is 4.28% of its float.